Lumida
/CVRX
⌘K
CVRx Inc

CVRx Inc

CVRX
$2.88USD+0.70%+0.02 today

MARKET CAP

76.7M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$2
$11

AI Summary

Stalk
StalkMedium

Yesterday’s bearish medium-term stance was invalidated by late-June’s F candle and Bullish Pivot Point closing above the 9/21 EMAs, signaling structural repair. CVRX now sits in an early Stage 1 consolidation below the 50 DMA with medium-term bias turned Bullish. Short-term timing is Neutral; execution should be deferred by stalking pullbacks into the 9/21 EMA support or lower consolidation boundary. A decisive close below the 9/21 EMA region would invalidate this bullish posture.

  • Devoted Health’s coverage decision increases institutional reimbursement and patient access for Barostim.
  • Q2 2026 revenue rose 16% YoY to $15.7 M; net loss narrowed to $14 M (–$0.53/sh), showing cost control.
  • Full-year revenue guidance cut from $63–67 M to $58–60 M; shares slid 60% on the revision.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$13.0M$22.5M$39.3M$51.3M$56.7M
YoY %+72.4%+74.9%+30.5%+10.4%
P / Sales9.7x17.1x16.1x5.6x3.3x
EV / Sales-0.7x13.1x14.8x4.7x3.1x
Gross Profit, Adj.$9.4M$17.5M$33.0M$43.0M$48.3M
YoY %+85.9%+89.1%+30.0%+12.5%
Margin %72.1%77.8%84.1%83.8%85.3%
EV / Gross Profit-0.9x16.8x17.6x5.7x3.6x
EBITDA, Adj.$-25.8M$-42.1M$-42.6M$-58.9M$-50.5M
YoY %-63.2%-1.1%-38.3%+14.2%
Margin %-197.9%-187.4%-108.4%-114.8%-89.2%
EV / EBITDA0.3x-7.0x-13.7x-4.1x-3.5x
EBIT$-26.0M$-42.5M$-43.1M$-59.5M$-51.3M
YoY %-63.8%-1.4%-38.0%+13.8%
Margin %-199.2%-189.3%-109.7%-116.0%-90.5%
EV / EBIT0.3x-6.9x-13.5x-4.1x-3.4x
Net Income$-43.1M$-41.4M$-41.2M$-60.0M$-53.3M
YoY %+3.8%+0.6%-45.5%+11.1%
Net Margin-330.5%-184.4%-104.8%-116.9%-94.1%
EPS (GAAP)-$4.16-$2.02-$1.99-$2.65-$2.04
YoY %+51.4%+1.5%-33.2%+23.0%